Symptomatic treatment of multiple sclerosis

被引:105
作者
Henze, T.
Rieckmann, P.
Toyka, K. V.
机构
[1] Reha Zentrum Nittenau, Rehabil Zentrum Neurol, DE-93149 Nittenau, Germany
[2] Univ Wurzburg, Dept Neurol, D-8700 Wurzburg, Germany
关键词
multiple sclerosis; symptomatic treatment; consensus guidelines; expert opinion; evidence-based medicine;
D O I
10.1159/000095699
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Besides immunomodulation and immunosuppression, the specific treatment of symptoms is an essential component of the overall management of multiple sclerosis (MS). Symptomatic treatment is aimed at the elimination or reduction of symptoms impairing the functional abilities and quality of life of the affected patients. Moreover, with symptomatic treatment the development of a secondary physical impairment due to an existing one may be avoided. Many therapeutic techniques as well as different drugs are used for the treatment of MS symptoms, but only a few of them have been investigated, especially in MS patients, and are approved by the national health authorities. Despite an overwhelming number of publications, only a few evidence-based studies exist and consensus reports are very rare, too. Therefore, it seemed necessary to develop a consensus statement on symptomatic treatment of MS comprising existing evidence-based literature as well as therapeutic experience of neurologists who have dealt with these problems over a long time. This consensus paper contains proposals for the treatment of the most common MS symptoms: disorders of motor function and coordination, of cranial nerve function, of autonomic, cognitive, and psychological functions as well as MS-related pain syndromes and epileptic seizures. Copyright (c) 2006 S. Karger AG, Basel.
引用
收藏
页码:78 / 105
页数:28
相关论文
共 273 条
[41]  
CHENG JS, 2005, NEUROSURG FOCUS, V18
[42]   Treating learning impairments improves memory performance in multiple sclerosis: a randomized clinical trial [J].
Chiaravalloti, ND ;
DeLuca, J ;
Moore, NB ;
Ricker, JH .
MULTIPLE SCLEROSIS JOURNAL, 2005, 11 (01) :58-68
[43]   Prolonged effect of botulinum toxin injection in the treatment of cricopharyngeal dysphagia: Case report and literature review [J].
Chiu, MJ ;
Chang, YC ;
Hsiao, TY .
DYSPHAGIA, 2004, 19 (01) :52-57
[44]   Depressive symptoms and severity of illness in multiple sclerosis: Epidemiologic study of a large community sample [J].
Chwastiak, L ;
Ehde, DM ;
Gibbons, LE ;
Sullivan, M ;
Bowen, JD ;
Kraft, GH .
AMERICAN JOURNAL OF PSYCHIATRY, 2002, 159 (11) :1862-1868
[45]   Lamotrigine adjunctive therapy in painful phenomena in MS: Preliminary observations [J].
Cianchetti, C ;
Zuddas, A ;
Randazzo, AP ;
Perra, L ;
Marrosu, MG .
NEUROLOGY, 1999, 53 (02) :433-433
[46]  
Clarke J, 2005, LANCET, V365, P764, DOI 10.1016/S0140-6736(05)17983-5
[47]   TETRAHYDROCANNABINOL FOR TREMOR IN MULTIPLE-SCLEROSIS [J].
CLIFFORD, DB .
ANNALS OF NEUROLOGY, 1983, 13 (06) :669-671
[48]   AMANTADINE TREATMENT OF FATIGUE ASSOCIATED WITH MULTIPLE-SCLEROSIS [J].
COHEN, RA ;
FISHER, M .
ARCHIVES OF NEUROLOGY, 1989, 46 (06) :676-680
[49]   AGA technical review on management of oropharyngeal dysphagia [J].
Cook, IJ ;
Kahrilas, PJ .
GASTROENTEROLOGY, 1999, 116 (02) :455-478
[50]   Functional benefits of dysphagia therapy using adjunctive sEMG biofeedback [J].
Crary, MA ;
Carnaby, GD ;
Groher, ME ;
Helseth, E .
DYSPHAGIA, 2004, 19 (03) :160-164